- Home
- STAA vs ANIP Comparison
STAA vs ANIP Comparison
Compare STAA & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAA
- ANIP
- Stock Information
- Founded
- STAA 1982
- ANIP 2001
- Country
- STAA United States
- ANIP United States
- Employees
- STAA N/A
- ANIP N/A
- Industry
- STAA Ophthalmic Goods
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- STAA Health Care
- ANIP Health Care
- Exchange
- STAA Nasdaq
- ANIP Nasdaq
- Market Cap
- STAA 1.3B
- ANIP 1.3B
- IPO Year
- STAA N/A
- ANIP N/A
- Fundamental
- Price
- STAA $26.32
- ANIP $55.10
- Analyst Decision
- STAA Buy
- ANIP Buy
- Analyst Count
- STAA 7
- ANIP 6
- Target Price
- STAA $43.33
- ANIP $76.80
- AVG Volume (30 Days)
- STAA 641.1K
- ANIP 266.5K
- Earning Date
- STAA 10-30-2024
- ANIP 11-08-2024
- Dividend Yield
- STAA N/A
- ANIP N/A
- EPS Growth
- STAA 9.97
- ANIP N/A
- EPS
- STAA 0.44
- ANIP N/A
- Revenue
- STAA $341,224,000.00
- ANIP $555,456,000.00
- Revenue This Year
- STAA $8.45
- ANIP $23.69
- Revenue Next Year
- STAA $12.35
- ANIP $18.95
- P/E Ratio
- STAA $60.01
- ANIP N/A
- Revenue Growth
- STAA 10.01
- ANIP 23.60
- 52 Week Low
- STAA $25.89
- ANIP $48.20
- 52 Week High
- STAA $52.68
- ANIP $70.81
- Technical
- Relative Strength Index (RSI)
- STAA 32.92
- ANIP 38.95
- Support Level
- STAA $29.56
- ANIP $53.93
- Resistance Level
- STAA $32.00
- ANIP $63.23
- Average True Range (ATR)
- STAA 1.35
- ANIP 2.48
- MACD
- STAA -0.30
- ANIP -0.46
- Stochastic Oscillator
- STAA 7.04
- ANIP 12.58
About STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.